SEC Tracker
Get the app

Acadia Pharmaceuticals ACAD

Acadia Pharmaceuticals reports strong Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. GAAP total revenues of $342 million, up 22% year-over-year
  2. DAYBUE GAAP net sales of $140 million, up 39% year-over-year
  3. NUPLAZID GAAP net sales of $202 million, up 12% year-over-year
  4. Raises 2026 DAYBUE net sales guidance to $505–$520 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Acadia Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  2. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Cytokinetics CYTK public float $2.5B, Jun 30, 2025
  5. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025